Short answer
Abbott Laboratories (ABT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13.0B (up 14.5% year over year) with net income of $920M.
Q3 2026 key financials · XBRL
- Revenue
- $13.0B
- +14.5% YoY · +3.3% QoQ
- Net income
- $920M
- −44.0% YoY · −0.9% QoQ
- Operating margin
- 10.4%
- EPS (diluted)
- $0.53
- −43.0% YoY · +0.0% QoQ
Source: XBRL data from the Abbott Laboratories (ABT) Q3 2026 10-Q on SEC EDGAR. USD.
Abbott Laboratories Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $13.0B, up 14.5% YoY, with foreign exchange reducing growth by 0.3%
- Gross margin 50.3% vs 51.7% YoY, pressured by Exact Sciences amortization, higher costs, and foreign exchange
- Best segment Diagnostic Products, $3.3B, up 46.7%; worst Nutritional Products, $2.3B, up 5.1%
- Cash $4.1B vs $8.5B at December 31; operating cash flow $5.5B, down approximately $700M YoY
- Exact Sciences acquisition funded with $20.0B debt; $1.0B share repurchases and $0.63 quarterly dividend per share
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Abbott Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.